Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Authors' conclusion
The rate of new users of non-insulin, glucose-lowering drugs has increased in recent years and the prevalence of glucose-lowering drug use increases steadily. Glucose-lowering drugs are mainly prescribed by general practitioners, and the intensity, diversity and indications of glucose-lowering treatment are increasing.
Study context
- Population
- All individuals in Denmark initiating at least one non-insulin glucose-lowering drug, 2005–2021
- Participants
- 441,205 individuals
- Outcome
- Use of glucose-lowering drugs over time
- Follow-up
- 2005 to 2021
Methodological detailsmedical databases
- Medical databases
Main finding
As reported in the abstract
- Prevalence of use in entire adult population, 2005
- 2.1%
- Prevalence of use in entire adult population, 2021
- 5.0%
- Share of all glucose-lowering drug consumption in 2021: metformin
- 39%
- Share of consumption in 2021: insulin
- 17%
- Share of consumption in 2021: SGLT2i
- 17%
- Share of consumption in 2021: GLP-1 RA
- 16%
- Share of consumption in 2021: DPP-4i
- 7.5%
- Users on monotherapy
- 56%
- Users on dual therapy
- 28%
- Users on three drug classes
- 13%
- Users on four drug classes
- 2.8%
- Treatment regimens each covering >1% of users in 2021
- 15
- Glucose-lowering drugs prescribed by general practitioners
- 88%
Observational data: associations, not effects.
Original publication
Changes in the use of glucose‐lowering drugs: A Danish nationwide study. Diabetes Obes Metab. Published 3 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →